NewAmsterdam Pharma Company N.V. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number
NewAmsterdam Pharma Company N.V. (NAMS) had Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of 993.42 thousand shares as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber · last filed 2026-08-05
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 993.42K shares.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 1.01M shares.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 728.28K shares.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 724.91K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number as first filed |
|---|---|---|
| 2026-06-30 | 993.42K shares 10-Q · filed 2026-08-05 | |
| 2026-03-31 | 1.01M shares 10-Q · filed 2026-05-07 | |
| 2025-12-31 | 728.28K shares 10-Q · filed 2026-08-05 | |
| 2025-09-30 | 724.91K shares 10-Q · filed 2025-11-05 | |
| 2025-06-30 | 718.58K shares 10-Q · filed 2025-08-06 | |
| 2025-03-31 | 663.79K shares 10-Q · filed 2025-05-08 | |
| 2024-12-31 | 143.00K shares 10-K · filed 2026-02-18 | 608.78K shares 10-K · filed 2025-02-26 |
| 2024-09-30 | 608.78K shares 10-Q · filed 2024-11-06 | |
| 2024-06-30 | 608.78K shares 10-Q · filed 2024-08-07 | |
| 2024-03-31 | 608.78K shares 10-Q · filed 2024-05-08 | |
| 2023-12-31 | 608.78K shares 10-K · filed 2025-02-26 | |
| 2022-12-31 | 608.78K shares 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |